DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

NEWS RELEASE

Updated: June 27, 2018

Defense Health Program
Department of Defense Peer Reviewed Cancer Research Program
Funding Opportunities for Fiscal Year 2018 (FY18)

The FY18 Defense Appropriation provides $80 million (M) to the Department of Defense Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The PRCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY18 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in July 2018. Pre-application and application deadlines will be available when the Program Announcement is released. This pre-announcement should not be construed as an obligation by the government.

Congressionally Directed Topic Areas: To be considered for funding, applications for the FY18 PRCRP must address at least one of the Topic Areas as directed by Congress. Research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, or ovarian cancer will not be accepted.

The FY18 PRCRP Topic Areas are:

  • Adrenal Cancers
  • Bladder Cancer
  • Blood Cancers
  • Brain Cancer
  • Cancer in children, adolescents, and young adults*
  • Colorectal cancer
  • Immunotherapy+
  • Listeria-based reginmens for cancer
  • Liver cancer
  • Lymphoma
  • Melanoma and other skin cancers
  • Mesothelioma
  • Myeloma
  • Neuroblastoma
  • Pancreatic cancer
  • Pediatric brain tumors
  • Stomach cancer

*The definition of adolescents and young adults is derived from the National Cancer Institute (https://www.cancer.gov/types/aya) and can be considered to be people between the ages of 15 and 39 years. Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s). Research should be targeted toward children (ages 0-14 years), adolescents (ages 15-24 years) and/or young adults (ages 25-39 years).

+As derived from the National Cancer Institute Dictionary of Cancer terms (http://www.cancer.gov/publications/dictionaries/cancer-terms). Immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer. Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

The FY18 PRCRP Military Relevance Focus Areas are listed below:

To address the cancer health needs of both deployed and non-deployed personnel, their dependents, retirees, and Veterans, the FY18 PRCRP seeks to support studies that are responsive to at least one of Military Relevance Focus Areas listed below:

  • Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, environmental carcinogens, and stress)
  • Gaps in cancer prevention, screening, early detection, diagnosis, treatment, and/or survivorship that may impact mission readiness and the health and well-being of military members, Veterans, and their beneficiaries and the general public

Award Mechanism Eligibility Key Mechanism Elements Funding
Horizon Award Principal Investigator (PI): Predoctoral candidate within 2 years of completion of required coursework/laboratory rotations, successfully passed qualifying examinations, and is working in his/her Mentor’s laboratory application submission deadline

Or Postdoctoral fellow within 3 years of completion of terminal degree and is working in his/her Mentor’s laboratory at application submission deadline

Mentor: Investigators at or above the level of Assistant Professor (or equivalent); must have a proven publication and funding record in cancer research

PI and Mentor must be at the same organization.
  • Letter of Intent is required. An invitation to submit a full application is not required.
  • Supports junior-level scientists in conducting impactful research with the mentorship of an experienced cancer researcher (i.e., Mentor).
  • Must address at least one of the FY18 PRCRP Topic Areas.
  • Must address at least one of the FY18 PRCRP Military Relevance Focus Areas.
  • Preliminary data are not required.
  • Clinical trials are not allowed.
  • Maximum funding for the entire period of performance is $150,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 2 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the PRCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Wednesday, June 27, 2018